H2020-JTI-IMI2-2018-15-two-stage
H2020-JTI-IMI2-2018-15-two-stage
- Programme
- H2020
- Funded projects (dataset)
- 7
- EU contribution (sum)
- €165,608,085
- Portal deadline
- —
Leading topic in historical projects: IMI2-2018-15-01
Start here
Suggested partners for this call
Who coordinated consortia under this call, plus a complementary slice (topic leaders, research partners, or frequent non-coordinators). For industry lists, CSV export, and consortium size — open Proposal partner finder.
Top coordinators
Organisations that coordinated the most funded projects under this call.
Organisations strong on this topic
Broader signal: frequent participants across funded projects tagged with the same topic codes as this call (not limited to coordinators).
- EUROPEAN PATIENTS FORUM3 topic projects
- KU Leuven3 topic projects
- NOVARTIS3 topic projects
- PFIZER3 topic projects
- ABBVIE INC2 topic projects
- ASTRAZENECA AB2 topic projects
- ERASMUS MC2 topic projects
- GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED2 topic projects
- INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA2 topic projects
- JANSSEN PHARMACEUTICA NV2 topic projects
- LMU MUENCHEN2 topic projects
- Novo Nordisk2 topic projects
Frequent collaborators
Pairs that often appear together in the same funded project under this call.
- 3 shared
- ERASMUS MC · PFIZER3 shared
NL ↔ UK
- EUROPEAN PATIENTS FORUM · PFIZER3 shared
BE ↔ UK
- 3 shared
- 3 shared
- JANSSEN PHARMACEUTICA NV · ABBVIE INC3 shared
BE ↔ US
- JANSSEN PHARMACEUTICA NV · PFIZER3 shared
BE ↔ UK
- EUROPEAN PATIENTS FORUM · NOVARTIS3 shared
BE ↔ CH
- EUROPEAN PATIENTS FORUM · KU Leuven3 shared
BE ↔ BE
- 3 shared
- ABBVIE INC · PFIZER3 shared
US ↔ UK
- ABBVIE INC · ASTRAZENECA AB3 shared
US ↔ SE
- PFIZER · ASTRAZENECA AB3 shared
UK ↔ SE
- JANSSEN PHARMACEUTICA NV · ASTRAZENECA AB3 shared
BE ↔ SE
- 2 shared
- GRIT · JANSSEN PHARMACEUTICA NV2 shared
DK ↔ BE
- GRIT · EVOTEC INTERNATIONAL GMBH2 shared
DK ↔ DE
- ECRIN · UNIVERSITY OF MANCHESTER2 shared
FR ↔ UK
Proposal partner finder
One page with suggested coordinators, strong and industry partners, topic leaders, typical consortium size, similar projects — plus CSV or print / PDF export for your shortlist.
Typical consortium pattern
Derived from historical funded projects linked to this CORDIS call in Grantibase.
- Avg. orgs / project
- 33.86
- Median orgs / project
- 31
- Min / max orgs
- 12 – 59
Country presence
Participant rows (an org can appear in multiple countries if data varies).
- Germany40
- United Kingdom36
- Belgium23
- France21
- Spain16
- Netherlands15
- United States14
- Italy13
- Switzerland11
- Sweden8
- Denmark7
- Portugal6
- Austria5
- Luxembourg5
- Israel3
- Ireland3
- Greece2
- Romania2
Organization types
- university52 orgs · 68 rows
- company34 orgs · 59 rows
- research_institute41 orgs · 45 rows
- sme34 orgs · 39 rows
- other15 orgs · 18 rows
- public_body6 orgs · 8 rows
Topics in funded projects
- IMI2-2018-15-01IMI2-2018-15-01· 1 projects
- IMI2-2018-15-02IMI2-2018-15-02· 1 projects
- IMI2-2018-15-03IMI2-2018-15-03· 1 projects
- IMI2-2018-15-04IMI2-2018-15-04· 1 projects
- IMI2-2018-15-06IMI2-2018-15-06· 1 projects
- IMI2-2018-15-07IMI2-2018-15-07· 1 projects
- IMI2-2018-15-08IMI2-2018-15-08· 1 projects
Related funded projects
Largest EU contributions in this call — useful to see who already won funding on similar lines.
Open full project list in advanced search
| Project | Programme | EU contribution |
|---|---|---|
| ERA4TB EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS | H2020 | €89,815,600 |
| IDEA-FAST Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases | H2020 | €20,997,523 |
| ImmUniverse Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies | H2020 | €15,500,000 |
| EU-PEARL EU Patient- cEntric clinicAl tRial pLatform | H2020 | €12,004,953 |
| imSAVAR Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies | H2020 | €10,999,316 |
| PharmaLedger PharmaLedger | H2020 | €8,290,694 |
| COMBINE Collaboration for Prevention and Treatment of MDR Bacterial Infections | H2020 | €8,000,000 |